Pricing updated 2019-07-18. Prices are subject to change without notice.
VU0155041 is a positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4) with an EC50 value of 2.5 μM for glutamate response in a thallium flux assay.1 It is selective for mGluR4, exhibiting no effect on radioligand binding at 67 G protein-coupled receptors, ion channels, and transporters, and lacking antagonist activity at NMDA receptors in striatal medium spiny neurons at a concentration of 10 μM. In vivo, VU0155041 decreases catalepsy induced by haloperidol (Item No. 12014) and reverses askinesias induced by reserpine (Item No. 16474) in rat models of Parkinson’s disease. Chronic treatment with VU0155041 restores social behavior in the Oprm-/- mouse model of autism.2 It also increases the percentage of time spent in the open arms of the elevated plus maze, a measure of decreased anxiety, in mice.3
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Niswender, C.M., Johnson, K.A., Weaver, C.D., et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol. Pharmacol. 74(5), 1345-1358 (2008).
Becker, J.A., Clesse, D., Spiegelhalter, C., et al. Autistic-
Duvoisin, R.M., Villasana, L., Davis, M.J., et al. Opposing roles of mGluR8 in measures of anxiety involving non-